Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Baxter
Johnson and Johnson
Harvard Business School
Mallinckrodt

Last Updated: February 3, 2023

CLINICAL TRIALS PROFILE FOR LEDIPASVIR; SOFOSBUVIR


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Ledipasvir; Sofosbuvir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01473472 ↗ On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men Completed ANRS, Emerging Infectious Diseases Phase 3 2012-01-01 This phase III, multi-centre, comparative, double-blind, randomized trial on 2 parallel groups is designed to evaluate a strategy for the prevention of HIV infection including "on demand" antiretroviral pre-exposure with Truvada versus placebo, associated with overall prevention (counselling, condoms, sexually transmitted diseases (STD) screening, hepatitis B virus (HBV) and hepatitis A virus (HAV) vaccinations and post-exposure treatment of HIV infection) in men who have sex with men (MSM), exposed to the risk of HIV infection. Indeed recent studies have reported a higher incidence of new HIV infection in MSM as compared to the general population, new approaches to the prevention of HIV infection are, therefore, necessary in order to consider the limits of current strategies.
NCT01473472 ↗ On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men Completed French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) Phase 3 2012-01-01 This phase III, multi-centre, comparative, double-blind, randomized trial on 2 parallel groups is designed to evaluate a strategy for the prevention of HIV infection including "on demand" antiretroviral pre-exposure with Truvada versus placebo, associated with overall prevention (counselling, condoms, sexually transmitted diseases (STD) screening, hepatitis B virus (HBV) and hepatitis A virus (HAV) vaccinations and post-exposure treatment of HIV infection) in men who have sex with men (MSM), exposed to the risk of HIV infection. Indeed recent studies have reported a higher incidence of new HIV infection in MSM as compared to the general population, new approaches to the prevention of HIV infection are, therefore, necessary in order to consider the limits of current strategies.
NCT01701401 ↗ Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV Completed Gilead Sciences Phase 3 2012-09-01 The purpose of this study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir (LDV)/sofosbuvir (SOF) fixed-dose combination (FDC) tablets with or without ribavirin (RBV) administered for 12 and 24 weeks in treatment-naive subjects with chronic genotype 1 HCV infection.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ledipasvir; Sofosbuvir

Condition Name

Condition Name for Ledipasvir; Sofosbuvir
Intervention Trials
Hepatitis C 22
Hepatitis C Virus Infection 14
Hepatitis C, Chronic 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ledipasvir; Sofosbuvir
Intervention Trials
Hepatitis C 87
Hepatitis 62
Hepatitis A 41
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ledipasvir; Sofosbuvir

Trials by Country

Trials by Country for Ledipasvir; Sofosbuvir
Location Trials
United States 291
Canada 22
Egypt 19
Japan 14
Italy 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ledipasvir; Sofosbuvir
Location Trials
Texas 21
New York 20
California 20
Pennsylvania 14
North Carolina 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ledipasvir; Sofosbuvir

Clinical Trial Phase

Clinical Trial Phase for Ledipasvir; Sofosbuvir
Clinical Trial Phase Trials
Phase 4 22
Phase 3 24
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ledipasvir; Sofosbuvir
Clinical Trial Phase Trials
Completed 65
Unknown status 16
Recruiting 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ledipasvir; Sofosbuvir

Sponsor Name

Sponsor Name for Ledipasvir; Sofosbuvir
Sponsor Trials
Gilead Sciences 46
Cairo University 3
Assiut University 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ledipasvir; Sofosbuvir
Sponsor Trials
Other 113
Industry 53
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Merck
Medtronic
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.